普洛药业控股子公司6196万元项目环评获原则同意

Group 1 - The core point of the news is that Zhejiang Prodebang Pharmaceutical Co., Ltd., a subsidiary of Pro Pharmaceutical (SZ000739), has received preliminary approval for an environmental impact assessment for a project to upgrade its raw material drug production line, with a total investment of 61.96 million yuan [1] - The "A-share Green Report" project aims to enhance transparency in environmental information of listed companies by monitoring their environmental performance based on authoritative regulatory data from 31 provinces and 337 cities [1] - The latest A-share Green Weekly Report indicated that nine listed companies have recently exposed environmental risks [1] Group 2 - Pro Pharmaceutical's main business is in the pharmaceutical industry, accounting for 99.6% of its revenue, with other businesses making up 0.4% [3] - The company's market capitalization is 19.462 billion yuan, with projected revenues of 11.474 billion yuan for 2023, 12.022 billion yuan for 2024, and 7.764 billion yuan for the first three quarters of 2025 [4] - The net profit attributable to the parent company is expected to be 1.055 billion yuan for 2023, 1.031 billion yuan for 2024, and 700 million yuan for the first three quarters of 2025 [4]